

## Exploring the Current and Future Role of B-Cell Maturation Antigen-Directed Therapy in the Management of Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Updated analysis from the Phase II KarMMa study evaluating idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma demonstrated a median overall survival of approximately what value?
  - a. 3 months
  - b. 6 months
  - c. 1 year
  - d. 2 years
2. Which of the following toxicities was most commonly reported in the DREAMM-2 study with belantamab mafodotin (2.5mg/kg) in patients with multiple myeloma?
  - a. Diarrhea
  - b. Hypercalcemia
  - c. Respiratory infection
  - d. Keratopathy
3. Which of the following cell types generally has the highest expression of B-cell maturation antigen?
  - a. Myeloma cells
  - b. B cells
  - c. Plasma cells
4. Which of the following treatment-emergent adverse events were most common in patients receiving elranatamab as part of the MagnetisMM-1 trial?
  - a. Gastrointestinal toxicities
  - b. Hematologic toxicities
  - c. Respiratory toxicities
  - d. Ocular toxicities
5. Which of the following best describes the targets of trispecific antibodies, which are under preclinical investigation for efficacy in the treatment of multiple myeloma?
  - a. B cell, T cell, myeloma cell
  - b. B cell, NK cell, myeloma cell
  - c. T cell, NK cell, myeloma cell
  - d. Macrophage, T cell, myeloma cell